Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Madeline Fulmer's research focuses on the discovery and characterization of potential therapeutic agents, specifically protein kinase inhibitors. Her recent publication details the discovery of DA-143, a novel inhibitor of DNA-PKcs, which demonstrates improved solubility compared to existing compounds like NU7441. This work investigates the potential of small molecules to target DNA-activated protein kinase, an enzyme implicated in DNA damage response and cellular processes within tumor cells and T-lymphocytes. Fulmer collaborates with researchers at the University of Arkansas for Medical Sciences, including Randall R Rainwater, Brendan Frett, Ana Clara P. Azevedo‐Pouly, and Baku Acharya, contributing to a shared publication record.
Metrics
- h-index: 1
- Publications: 1
- Citations: 3
Selected Publications
-
Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024)
Collaboration Network
Top Collaborators
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
Similar Researchers
Based on overlapping research topics